V-Wave is a non-invasive acoustic wave treatment being used and studied for certain aspects of female sexual health. Low-intensity acoustic energy is applied externally to targeted vulvovaginal tissues with the goal of influencing local blood flow and tissue response.
V-Wave may be considered for appropriately selected women experiencing changes in sexual sensation, arousal or other aspects of sexual function. However, female sexual dysfunction can have many causes, including hormonal changes, medications, menopause, pelvic floor dysfunction, pain disorders and psychological or relationship factors.
For this reason, treatment at R2 Medical Clinic begins with an individualized evaluation to determine whether V-Wave or another treatment option may be appropriate.
V-Wave uses low-intensity acoustic waves applied to targeted external tissues. Similar forms of acoustic-wave therapy have been studied in other areas of medicine for their effects on local circulation and tissue response.
Proposed mechanisms include changes in local blood flow, cellular signaling and vascular responses. These mechanisms have been studied more extensively in other applications than in female sexual dysfunction.
Research specifically evaluating acoustic-wave therapy for female sexual function remains limited, and additional controlled clinical studies are needed to determine its effectiveness, optimal treatment protocols and durability of results.

Acoustic and other energy-based therapies have been investigated for female sexual dysfunction and menopause-related vulvovaginal symptoms. Some studies have reported improvements in measures of sexual function and vaginal symptoms.
However, research specifically supporting low-intensity acoustic or shockwave therapy for female sexual dysfunction remains limited. Treatment protocols vary, and there is not yet enough high-quality evidence to establish which patients are most likely to benefit, the optimal treatment protocol or how long potential benefits may last.
Female sexual dysfunction is also multifactorial. Changes in desire, arousal, orgasm or sexual comfort may result from hormonal, medication-related, pelvic floor, vulvovaginal, psychological or relationship factors that acoustic-wave therapy does not necessarily address.
At R2 Medical Clinic, V-Wave is considered as one potential treatment option following an individualized evaluation rather than as a universal treatment for female sexual dysfunction.
6-8
Sessions Recommended
15-20
Minutes Per Session
0
Anesthesia Required
0
Days Downtime
Promotes angiogenesis for improved circulation to intimate tissue.
Improves tissue sensitivity and natural lubrication.
Can be paired with O-Shot therapy for maximum benefit.
Your provider reviews your symptoms, medical history, medications, menopausal status and other factors that may contribute to changes in sexual function. This evaluation helps determine whether V-Wave may be appropriate.
Acoustic waves are applied to targeted external tissues using a handheld treatment device. A typical session takes approximately 15–20 minutes. Anesthesia is generally not required.
Most patients can return to normal daily activities following treatment. Temporary sensitivity or discomfort may occur. Your provider will discuss the recommended treatment schedule and follow-up based on your individual treatment plan.
V-Wave is not necessarily appropriate for every woman experiencing sexual concerns.
Sexual dysfunction may be related to:
Identifying these contributors may lead to treatments other than—or in addition to—V-Wave.
Depending on the cause of your symptoms, treatment may include vaginal moisturizers or lubricants, local vaginal estrogen, pelvic floor physical therapy, medication adjustment, sex therapy or counseling, hormone therapy when clinically appropriate, prescription medications for selected women with HSDD, PRP or other individualized treatment approaches.
Learn more about our comprehensive approach to Female Sexual Dysfunction.
Medically reviewed by Erik Natkin, DO — Founder, R2 Medical Clinic. Content last reviewed August 2026.